adalimumab + etanercept + golimumab

This is a combination of three tumor necrosis factor (TNF) inhibitors—adalimumab, etanercept, and golimumab. Each is a biologic agent that targets and neutralizes TNF-alpha, a cytokine involved in systemic inflammation. These drugs are individually approved for the treatment of various autoimmune and inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease (adalimumab and golimumab), ulcerative colitis (adalimumab and golimumab), juvenile idiopathic arthritis, and plaque psoriasis. All three agents act by binding to TNF-alpha (both soluble and transmembrane forms), thereby preventing its interaction with cell surface receptors that mediate inflammatory responses[1][3][6][8]. While each drug is used as monotherapy or in combination with non-biologic DMARDs like methotrexate[1][4], the concurrent use of multiple biologic TNF inhibitors together is not recommended due to increased risk of serious infections and lack of evidence for added efficacy[9]. There are no known marketed products or clinical guidelines supporting the combined use of all three agents simultaneously.

Brand names

EnbrelEticovoErelziBenepaliNepextoSimponiSimponi AriaHumiraAmgevitaAmjevitaAmsparityCyltezoHefiyaHukyndraHulioHyrimozIdacioImraldiLibmyrisSimlandiYuflymaYusimry